AlphaGrep UK’s Moderna MRNA Stock Holding History

AlphaGrep UK’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-8,106	Closed	-$568K	–	887
2026 Q2	$568K	Buy	+8,106	New	+$419K	0.17%	181

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Theleme Partners London, United Kingdom $2.62B AUM 125.04% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

AlphaGrep UK's MRNA Position: Q3 2026 in Review

AlphaGrep UK sold out of Moderna (MRNA) in Q3 2026, closing a stake of 8,106 shares — an estimated $568K sold.

AlphaGrep UK first reported a position in MRNA in Q2 2026 and held it in 1 quarter. The position peaked at $568K in Q2 2026. 858 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

AlphaGrep UK reported no remaining Moderna position as of Q3 2026 after selling out during the quarter.
AlphaGrep UK sold 8,106 Moderna shares in Q3 2026, an estimated $568K.
AlphaGrep UK first reported a position in Moderna in Q2 2026 and held it in 1 quarter.
AlphaGrep UK's Moderna position peaked at $568K in Q2 2026.
858 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on AlphaGrep UK's 13F filing for Q3 2026, filed 12 Nov 2026.